Deloitte and Vineti join forces to support personalized medicine development

Deloitte and Vineti announced that they have entered into a teaming agreement, announcing their intent to work together to support life sciences innovators by integrating and scaling their respective supply chain and patient engagement platforms to enable more efficient access to next-generation cellular therapies.

Vineti’s cell and gene therapy platform provides a digital “platform of record” for individualized therapies and Deloitte’s ConvergeHEALTH Patient Connect™ platform streamlines and improves patient and health system engagement at pharmaceutical, medical device and hub vendors. Together, the Vineti and ConvergeHEALTH Patient Connect™ platforms can offer a holistic one-stop solution to support life sciences innovators and health care professionals with the information systems to deliver on the promise of personalized medicine.

In individualized medicine, the patient is a key part of the therapeutic process, the product and the treatment. The combination of Vineti’s proven expertise in delivering cell and gene therapies and Deloitte’s deep knowledge of the health care ecosystem and its time-tested (or something similar) ConvergeHEALTH Patient Connect platform will help enable life sciences innovators to expand the role of personalized medicines in mainstream health care.

Vineti is the first cloud-based software platform to safely and efficiently move patient-based personalized therapies into mainstream medicine at scale. The Vineti platform – configurable, cloud-based, secure and scalable – brings the best of enterprise software to next-generation pharmaceutical science. Vineti’s solution aligns, manages, integrates and simplifies all the major steps and stakeholders in the inherently complex cell and gene therapy process, helping everyone from health care providers to biopharma and manufacturers exert efficiency and control to optimize the patient’s therapy journey. The Vineti platform is currently serving patients in more than 65 leading medical centers and expanding worldwide.

ConvergeHEALTH Patient Connect currently supports more than 300,000 patients globally in over 17 countries. Deloitte’s ConvergeHEALTH suite of software solutions are built with the understanding that, in today’s market, truly actionable insights are derived from a combination of real-world information, evidence and experience, not just data. Powered by Deloitte’s virtually unparalleled industry experience, the ConvergeHEALTH solutions are designed specifically to solve the biggest business and operational challenges that the health care and life science industries face.

By working with Vineti and ConvergeHEALTH by Deloitte, life sciences innovators will be able to scale their personalized therapies, connect with even more health care providers, and provide more therapies to more patients than ever before.

Headquartered in UK, Deloitte Touche Tohmatsu Limited is a multinational professional services network and one of the “Big Four” accounting organizations and the largest professional services network in the world by revenue and number of professionals.

Vineti is the first commercial, configurable cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by multinational conglomerate General Electric (Boston, USA) and the Mayo Clinic (Rochester, Minnesota, USA) to solve the key challenges patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of individualized therapies.